Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery
Purpose: To study the role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Method: Thirty eyes of 30 patients with a primary rhegmatogenous retinal detachment and proliferative vitreoretinopathy of stage D1 or more advanced were included in the stud...
Gespeichert in:
Veröffentlicht in: | Clinical & experimental ophthalmology 2002-10, Vol.30 (5), p.348-351 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 351 |
---|---|
container_issue | 5 |
container_start_page | 348 |
container_title | Clinical & experimental ophthalmology |
container_volume | 30 |
creator | Kumar, Atul Nainiwal, Sanjeev Choudhary, Indranil Tewari, Hem K Verma, Lalit K |
description | Purpose: To study the role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.
Method: Thirty eyes of 30 patients with a primary rhegmatogenous retinal detachment and proliferative vitreoretinopathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of daunorubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery.
Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group.
Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment. |
doi_str_mv | 10.1046/j.1442-9071.2002.00554.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72065432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72065432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</originalsourceid><addsrcrecordid>eNqNkFtP9CAQhonReP4LhivvWoFCS5Pvxmx018RoYjxcEtoOLvt12xWo7v572UP01gzJTJj3HZgHIUxJSgnPr2Yp5ZwlJSloyghhKSFC8HS5h45_Gvu7OueEH6ET72ckqliWH6IjyhjNqCiPUf3Ut4B7gxs9dL0bKlvbDm_O1FY22O4dL1zfWgNOB_sJ-NMGB72D2OoXOkxXWJsADm9udIsbCLqezqEL2A_uHdzqDB0Y3Xo43-VT9HJ78zyaJPeP47vR9X1Sc8J4kkvNGslEWUEpc6CaAS0EI0abKqNQUs1jCFmRksVoZB73y4yQXFeyliY7RZfbufHDHwP4oObW19C2uoN-8KpgJBc8Y1Eot8La9d47MGrh7Fy7laJErQGrmVqzU2uOag1YbQCrZbRe7N4Yqjk0v8Yd0Sj4txV82RZWfx6sRjePsYj2ZGu3PsDyx67df5UXWSHU28NYsdfJRJIxU8_ZNwb5mh0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72065432</pqid></control><display><type>article</type><title>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Kumar, Atul ; Nainiwal, Sanjeev ; Choudhary, Indranil ; Tewari, Hem K ; Verma, Lalit K</creator><creatorcontrib>Kumar, Atul ; Nainiwal, Sanjeev ; Choudhary, Indranil ; Tewari, Hem K ; Verma, Lalit K</creatorcontrib><description>Purpose: To study the role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.
Method: Thirty eyes of 30 patients with a primary rhegmatogenous retinal detachment and proliferative vitreoretinopathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of daunorubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery.
Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group.
Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.</description><identifier>ISSN: 1442-6404</identifier><identifier>EISSN: 1442-9071</identifier><identifier>DOI: 10.1046/j.1442-9071.2002.00554.x</identifier><identifier>PMID: 12213159</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Pty</publisher><subject>Antibiotics, Antineoplastic - therapeutic use ; daunorubicin ; Daunorubicin - therapeutic use ; Female ; Humans ; Injections ; intravitreal ; Male ; Middle Aged ; proliferative vitreoretinopathy ; retinal detachment ; Retinal Detachment - complications ; Retinal Detachment - surgery ; retinal pigment epithelium ; Scleral Buckling ; Visual Acuity ; Vitrectomy ; Vitreoretinopathy, Proliferative - etiology ; Vitreoretinopathy, Proliferative - prevention & control ; Vitreous Body</subject><ispartof>Clinical & experimental ophthalmology, 2002-10, Vol.30 (5), p.348-351</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</citedby><cites>FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1442-9071.2002.00554.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1442-9071.2002.00554.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12213159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Atul</creatorcontrib><creatorcontrib>Nainiwal, Sanjeev</creatorcontrib><creatorcontrib>Choudhary, Indranil</creatorcontrib><creatorcontrib>Tewari, Hem K</creatorcontrib><creatorcontrib>Verma, Lalit K</creatorcontrib><title>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</title><title>Clinical & experimental ophthalmology</title><addtitle>Clin Exp Ophthalmol</addtitle><description>Purpose: To study the role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.
Method: Thirty eyes of 30 patients with a primary rhegmatogenous retinal detachment and proliferative vitreoretinopathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of daunorubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery.
Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group.
Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.</description><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>daunorubicin</subject><subject>Daunorubicin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Injections</subject><subject>intravitreal</subject><subject>Male</subject><subject>Middle Aged</subject><subject>proliferative vitreoretinopathy</subject><subject>retinal detachment</subject><subject>Retinal Detachment - complications</subject><subject>Retinal Detachment - surgery</subject><subject>retinal pigment epithelium</subject><subject>Scleral Buckling</subject><subject>Visual Acuity</subject><subject>Vitrectomy</subject><subject>Vitreoretinopathy, Proliferative - etiology</subject><subject>Vitreoretinopathy, Proliferative - prevention & control</subject><subject>Vitreous Body</subject><issn>1442-6404</issn><issn>1442-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkFtP9CAQhonReP4LhivvWoFCS5Pvxmx018RoYjxcEtoOLvt12xWo7v572UP01gzJTJj3HZgHIUxJSgnPr2Yp5ZwlJSloyghhKSFC8HS5h45_Gvu7OueEH6ET72ckqliWH6IjyhjNqCiPUf3Ut4B7gxs9dL0bKlvbDm_O1FY22O4dL1zfWgNOB_sJ-NMGB72D2OoXOkxXWJsADm9udIsbCLqezqEL2A_uHdzqDB0Y3Xo43-VT9HJ78zyaJPeP47vR9X1Sc8J4kkvNGslEWUEpc6CaAS0EI0abKqNQUs1jCFmRksVoZB73y4yQXFeyliY7RZfbufHDHwP4oObW19C2uoN-8KpgJBc8Y1Eot8La9d47MGrh7Fy7laJErQGrmVqzU2uOag1YbQCrZbRe7N4Yqjk0v8Yd0Sj4txV82RZWfx6sRjePsYj2ZGu3PsDyx67df5UXWSHU28NYsdfJRJIxU8_ZNwb5mh0</recordid><startdate>200210</startdate><enddate>200210</enddate><creator>Kumar, Atul</creator><creator>Nainiwal, Sanjeev</creator><creator>Choudhary, Indranil</creator><creator>Tewari, Hem K</creator><creator>Verma, Lalit K</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200210</creationdate><title>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</title><author>Kumar, Atul ; Nainiwal, Sanjeev ; Choudhary, Indranil ; Tewari, Hem K ; Verma, Lalit K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>daunorubicin</topic><topic>Daunorubicin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Injections</topic><topic>intravitreal</topic><topic>Male</topic><topic>Middle Aged</topic><topic>proliferative vitreoretinopathy</topic><topic>retinal detachment</topic><topic>Retinal Detachment - complications</topic><topic>Retinal Detachment - surgery</topic><topic>retinal pigment epithelium</topic><topic>Scleral Buckling</topic><topic>Visual Acuity</topic><topic>Vitrectomy</topic><topic>Vitreoretinopathy, Proliferative - etiology</topic><topic>Vitreoretinopathy, Proliferative - prevention & control</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Atul</creatorcontrib><creatorcontrib>Nainiwal, Sanjeev</creatorcontrib><creatorcontrib>Choudhary, Indranil</creatorcontrib><creatorcontrib>Tewari, Hem K</creatorcontrib><creatorcontrib>Verma, Lalit K</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Atul</au><au>Nainiwal, Sanjeev</au><au>Choudhary, Indranil</au><au>Tewari, Hem K</au><au>Verma, Lalit K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</atitle><jtitle>Clinical & experimental ophthalmology</jtitle><addtitle>Clin Exp Ophthalmol</addtitle><date>2002-10</date><risdate>2002</risdate><volume>30</volume><issue>5</issue><spage>348</spage><epage>351</epage><pages>348-351</pages><issn>1442-6404</issn><eissn>1442-9071</eissn><abstract>Purpose: To study the role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.
Method: Thirty eyes of 30 patients with a primary rhegmatogenous retinal detachment and proliferative vitreoretinopathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of daunorubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery.
Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group.
Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Pty</pub><pmid>12213159</pmid><doi>10.1046/j.1442-9071.2002.00554.x</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1442-6404 |
ispartof | Clinical & experimental ophthalmology, 2002-10, Vol.30 (5), p.348-351 |
issn | 1442-6404 1442-9071 |
language | eng |
recordid | cdi_proquest_miscellaneous_72065432 |
source | MEDLINE; Wiley Online Library All Journals |
subjects | Antibiotics, Antineoplastic - therapeutic use daunorubicin Daunorubicin - therapeutic use Female Humans Injections intravitreal Male Middle Aged proliferative vitreoretinopathy retinal detachment Retinal Detachment - complications Retinal Detachment - surgery retinal pigment epithelium Scleral Buckling Visual Acuity Vitrectomy Vitreoretinopathy, Proliferative - etiology Vitreoretinopathy, Proliferative - prevention & control Vitreous Body |
title | Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A44%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20daunorubicin%20in%20inhibiting%20proliferative%20vitreoretinopathy%20after%20retinal%20detachment%20surgery&rft.jtitle=Clinical%20&%20experimental%20ophthalmology&rft.au=Kumar,%20Atul&rft.date=2002-10&rft.volume=30&rft.issue=5&rft.spage=348&rft.epage=351&rft.pages=348-351&rft.issn=1442-6404&rft.eissn=1442-9071&rft_id=info:doi/10.1046/j.1442-9071.2002.00554.x&rft_dat=%3Cproquest_cross%3E72065432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72065432&rft_id=info:pmid/12213159&rfr_iscdi=true |